Urothelial Carcinoma
Urothelial Carcinoma
Advertisement
Pooja Ghatalia, MDMuscle Invasive Urothelial Carcinoma | February 15, 2025
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
View More
Brandon TwyfordAdvanced Urothelial Carcinoma | February 14, 2025
EV+P continues to show superior efficacy and durable responses in previously untreated locally advanced or metastatic UC.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 14, 2025
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Matthew Galsky, MDMuscle Invasive Urothelial Carcinoma | February 14, 2025
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
Sia Daneshmand, MDNon-Muscle Invasive Urothelial Carcinoma | February 14, 2025
Dr. Daneshmand provides overviews and updates from three clinical trials involving cretostimogene for high-risk NMIBC.
Emily MenendezMuscle Invasive Urothelial Carcinoma | February 13, 2025
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | February 13, 2025
New research evaluated the efficacy and safety of durvalumab with intravesical gem/doce in a cohort from ADAPT-BLADDER.
Emily MenendezMuscle Invasive Urothelial Carcinoma | February 13, 2025
Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups.
Jordan Ciuro, MDProstate Cancer | February 12, 2025
Dr. Ciuro previews the potential practice-changing research in prostate, bladder, and kidney cancers from ASCO GU 2025.
Karine Tawagi, MDUrothelial Carcinoma | February 10, 2025
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on CheckMate 274, NIAGRA, and more.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | February 6, 2025
This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression.
Daniel M. Geynisman, MDMuscle Invasive Urothelial Carcinoma | February 4, 2025
Dr. Geynisman shares insights on the feasibility of bladder-sparing approaches in treating muscle-invasive bladder cancer.
Emily MenendezMuscle Invasive Urothelial Carcinoma | January 29, 2025
Using mpMRI before TURBT may be beneficial for patients with suspected MIBC.
Katie S. Murray, DO, MSUpper Tract Urothelial Carcinoma | January 23, 2025
Dr. Murray and Laura Bauer share their experiences treating patients with UTUC using mitomycin gel.
Raveen Syan, MD, FPMRSUrothelial Carcinoma | January 21, 2025
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Raveen Syan, MD, FPMRSUrothelial Carcinoma | January 21, 2025
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Yair Lotan, MDUrothelial Carcinoma Diagnostics | January 15, 2025
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | January 13, 2025
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Emily MenendezAdvanced Urothelial Carcinoma | January 10, 2025
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
Daniel M. Geynisman, MDMuscle Invasive Urothelial Carcinoma | January 10, 2025
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
Advertisement
Advertisement
Advertisement